Baseline characteristics of patients
| Characteristics . | Values . |
|---|---|
| Median age (range), y | 62 (23-74) |
| Sex, n (%) | |
| Male | 8 (53) |
| Female | 7 (47) |
| Median ECOG score (range) | 1 (0-2) |
| CNSL, n (%) | |
| PCNSL | 9 (60) |
| SCNSL | 6 (40) |
| Disease status, n (%) | |
| Recurrent PCNSL or SCNSL | 9 (60) |
| Refractory PCNSL or SCNSL | 3 (20) |
| Newly diagnosed SCNSL | 3 (20) |
| Newly diagnosed PCNSL | 0 (0) |
| CNS involvement, n (%) | |
| Brain | 5 (33) |
| CSF | 2 (13) |
| Brain and CSF | 7 (47) |
| Brain and eye | 1 (7) |
| Prior treatment in r/r disease, n (%); n = 12 | |
| Chemotherapy | 12 (100) |
| HD-MTX chemotherapy | 12 (100) |
| HD-MTX + alkylator | 9 (75) |
| Rituximab | 12 (100) |
| Radiation | 1 (8) |
| Stem cell transplant | 1 (8) |
| HD-MTX at recurrence | 3 (25) |
| Median number of prior regimens (range) | 1 (0-2) |
| Corticosteroids at enrollment, n (%) | 5 (33) |
| Characteristics . | Values . |
|---|---|
| Median age (range), y | 62 (23-74) |
| Sex, n (%) | |
| Male | 8 (53) |
| Female | 7 (47) |
| Median ECOG score (range) | 1 (0-2) |
| CNSL, n (%) | |
| PCNSL | 9 (60) |
| SCNSL | 6 (40) |
| Disease status, n (%) | |
| Recurrent PCNSL or SCNSL | 9 (60) |
| Refractory PCNSL or SCNSL | 3 (20) |
| Newly diagnosed SCNSL | 3 (20) |
| Newly diagnosed PCNSL | 0 (0) |
| CNS involvement, n (%) | |
| Brain | 5 (33) |
| CSF | 2 (13) |
| Brain and CSF | 7 (47) |
| Brain and eye | 1 (7) |
| Prior treatment in r/r disease, n (%); n = 12 | |
| Chemotherapy | 12 (100) |
| HD-MTX chemotherapy | 12 (100) |
| HD-MTX + alkylator | 9 (75) |
| Rituximab | 12 (100) |
| Radiation | 1 (8) |
| Stem cell transplant | 1 (8) |
| HD-MTX at recurrence | 3 (25) |
| Median number of prior regimens (range) | 1 (0-2) |
| Corticosteroids at enrollment, n (%) | 5 (33) |